{"id":"W3088332096","doi":"10.1016/j.annonc.2020.08.659","title":"545P Preclinical profile of EPI-7386, a second-generation N-terminal domain androgen receptor inhibitor for the treatment of prostate cancer","year":2020,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Daiichi Sankyo Europe; Loxo Oncology; Chugai Pharmaceutical; Shionogi; Pfizer Japan; Genentech; Eli Lilly Japan; Eisai; Astellas Pharma; Dainippon Sumitomo Pharma; Yakult Honsha; Sanofi; Kyowa Hakko Kirin; Ignyta; Eli Lilly and Company; Ono Pharmaceutical; Pfizer; Incyte; Taiho Pharmaceutical; GlaxoSmithKline; Teijin Pharma; Daiichi-Sankyo; Amgen; Bayer Yakuhin; Rakuten Medical; AstraZeneca; Bristol-Myers Squibb","keywords":"Enzalutamide; Androgen receptor; Prostate cancer; LNCaP; Medicine; In vivo; Tolerability; Cancer research; Pharmacology; Reporter gene; Cancer; Internal medicine; Gene expression; Biology; Gene; Adverse effect; Biochemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002988429,0.0005757081,0.0005446069,0.0002953607,0.0002209857,0.0004923088,0.0004498831,0.0003803986,0.006322412],"category_scores_gemma":[0.0001949824,0.0002107723,0.0004546246,0.0002349301,0.0002982123,0.000345761,0.0001163906,0.001537079,0.001262792],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003823635,"about_ca_system_score_gemma":0.001290345,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003158375,"about_ca_topic_score_gemma":0.006005801,"domain_scores_codex":[0.9999141,0.00002045734,0.000003887416,0.000009895956,0.00001452068,0.00003705893],"domain_scores_gemma":[0.9998976,0.00001237816,0.00001339759,0.000006183907,0.00001396626,0.0000565281],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0761833,0.02671086,0.00231228,0.00103065,0.0005977085,0.0005961577,0.0001919379,0.008742797,0.6388168,0.001880321,0.02086806,0.2220691],"study_design_scores_gemma":[0.03339296,0.4274256,0.0331783,0.0001616453,0.001648625,0.002621898,0.0002939339,0.01072071,0.4250369,0.0008128813,0.06454646,0.0001601029],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9634123,0.01081747,0.003580755,0.0009106257,0.0002906366,0.0006204774,0.00433058,0.0006862989,0.01535084],"genre_scores_gemma":[0.9682789,0.008999725,0.001855514,0.0004516718,0.00009215418,0.0002143248,0.005073017,0.00005910733,0.01497561],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006322412,"threshold_uncertainty_score":0.02115059,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1986108235554401,"score_gpt":0.462339251889346,"score_spread":0.2637284283339059,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}